Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Comment by CurlyMickon May 15, 2014 8:42pm
161 Views
Post# 22567859

RE:RE:RE:RE:RE:RE:RE:Global company's DD

RE:RE:RE:RE:RE:RE:RE:Global company's DDHey all Fellow Kane holders;

I think Champ's intuition or tacit knowledge is right. The Big Pharma deal for DD is pretty much done. Whoopee...we may end up with marketing for animal wound cleaning and StrixNB.

I couldn't care really...except for the segue value of such a deal.

Just proving that the pipeline is worth looking at ...through cats that bite, dogs with bad breath and for the elimination of bacteria laden scum in animals is only one small step.

Kane's management does things slowly and methodically, which for us anxious holders can be frustrating, but they haven't lied or misled us once, which is very encouraging and appreciated to this holder of many juniors that have lied to me and disappointed many others.

Dispersin B and all the positive tests for potential human applications is what makes me hang on to my shares. The science is there. Read about it by simply googling and do your own DD, but the discovery which is a Kane trademark works.

I'm looking forward to hearing more on June 4th.

Curly
Bullboard Posts